Abiomed (Nasdaq:ABMD) posted fourth-quarter results today that beat the overall consensus on Wall Street. The Danvers, Massachusetts-based company reported profits of $60.3 million, or $1.31 per share, on sales of $269.9 million for the three months ended December 31, for a bottom-line gain of 6.1% on sales growth of 11.86% compared with Q4 2021. Adjusted […]
Abiomed
Abiomed announces first Impella BTR heart pump implant
Abiomed (Nasdaq:ABMD) today announced the first patient in the world was successfully treated with its Impella Bridge-to-Recovery (BTR) as part of an early feasibility study. The first implant was performed by Dr. Duc Thinh Pham and Dr. Jane Wilcox at Northwestern Medicine Bluhm Cardiovascular Institute in Chicago. Impella BTR is a forward flow heart pump implanted […]
First patient in Japan treated with Abiomed’s Impella 5.5 with SmartAssist
Abiomed (Nasdaq:ABMD) announced today that the first patient in Japan was successfully treated with its Impella 5.5 with SmartAssist. The first Impella 5.5 with SmartAssist procedure in Japan took place at Osaka Police Hospital. The treated patient was an 82-year-old man treated for cardiogenic shock. “Our facility is proud to be the first in Japan […]
These 10 medtech companies’ stocks performed best in 2021
Following a year like no other in 2020, 2021 was when many looked to rebound — including the medtech industry. A number of medtech companies followed up a challenging, pandemic-enveloped year with impressive performances. Plenty of them had already proven in 2020 that they were capable of a quick bounce-back. Here are 10 medtech companies […]
Abiomed reports $261M in sales in Q3 results
Abiomed (NSDQ:ABMD) today posted third-quarter results that beat the overall consensus on Wall Street. The Danvers, Massachusetts–based heart device company reported profits of $45.8 million, or $1.00 per share, on sales of $261.2 million for the three months ended Dec. 31, 2021, on sales growth of 12.74% compared with Q4 2020. Adjusted to exclude one-time […]
Artificial heart developer BiVacor taps former Abiomed exec as CEO
BiVacor this week announced that former Abiomed executive Thomas Vassiliades was appointed CEO, effective immediately. Prior to joining the company, Vassiliades was most recently the general manager of the surgery and heart failure business at Abiomed. He has also served as the chief medical officer of the coronary and structural heart business of Medtronic, and […]
Abiomed picks up regulatory wins in U.S., Asia
Abiomed (NSDQ:ABMD) announced today that regulators in three different countries granted new approvals to Impella surgical products. Danvers, Massachusetts-based Abiomed won FDA early feasibility study (EFS) investigational device exemption (IDE) for the Impella BTR (bridge-to-recovery), while the Impella 5.5 with SmartAssist won approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and Hong Kong’s Medical […]
Abiomed beats The Street in Q2, lowers full-year outlook
Abiomed (NSDQ:ABMD) posted second-quarter results this week that beat the overall consensus on Wall Street. The Danvers, Massachusetts-based cardiovascular device company reported profits of $56.95 million, or $1.24 per share, on sales of $248.1 million for the three months ended September 30, for a bottom-line loss of -8.5% on sales growth of 18.3% compared with Q2 […]
FDA grants breakthrough device designation for Abiomed’s Impella ECP heart pump
Abiomed (NSDQ:ABMD) today announced that the FDA has granted breakthrough device designation for its Impella ECP expandable percutaneous heart pump. Danvers, Mass.-based Abiomed designed the Impella ECP heart pump to be compatible with small-bore access and closure techniques. It measures 3 mm in diameter when inserted and removed from the body. It expands in the heart […]
MedTech 100 roundup: Industry ticks up again
The medtech industry has been rising for weeks and the latest seven-day stretch was no exception as stocks ticked up again. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 6) at 119.41 points, marking a 0.5% rise from the previous week’s tally of 118.86 […]
Abiomed beats The Street in Q1, boosts full-year revenue guidance
Abiomed (NASDAQ: ABMD) posted first-quarter results that beat the consensus forecast on Wall Street, with the company boosting its revenue growth forecast to 22–24% for the fiscal year. The Danvers, Mass.–based maker of circulatory and oxygenation support devices reported a loss of –$26.5 million, or –59¢ per share, on sales of $252.5 million for the […]
